Menu
Back to Journals » OncoTargets and Therapy » Volume 11
NOP7 interacts with β-catenin and activates β-catenin/TCF signaling in hepatocellular carcinoma cells
Authors Wu N, Zhao J, Yuan Y, Lu C, Zhu W, Jiang Q
Received 4 February 2018
Accepted for publication 23 June 2018
Published 1 October 2018 Volume 2018:11 Pages 6369—6376
DOI https://doi.org/10.2147/OTT.S164601
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Samir Farghaly
Nan Wu,1 Jing Zhao,2,3 Youhua Yuan,4 Chuanjia Lu,1 Wenjing Zhu,1 Qun Jiang1
1Department of Clinical Laboratory, Shanghai Stomatological Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Cancer Metastasis Institute, Fudan University, Shanghai, People’s Republic of China; 4Department of Clinical Laboratory, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China
Background: The hyperactivation of β-catenin signaling is frequently observed in clinical hepatocellular carcinoma (HCC) samples. Further understanding the mechanisms involved in activating β-catenin/TCF signaling would benefit the treatment of HCC.
Method and results: Here, it was found that NOP7 was a binding partner of β-catenin. NOP7 strengthened the interaction between β-catenin and TCF4, which led to the activation of β-catenin/TCF signaling. The upregulation of NOP7 in HCC promoted the growth (in both liquid culture and soft agar) and migration of HCC cancer cells.
Conclusion: Taken together, we have demonstrated the oncogenic functions of NOP7 in HCC, suggesting that targeting NOP7 would benefit the treatment of HCC.
Keywords: hepatocellular carcinoma, NOP7, β-catenin/TCF pathway, cell growth, cell migration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.